Michael Hallek, MD | Authors

""UNIVERSITY OF WISCONSIN MEDICAL FOUNDATION,INC""

601 HANDEYSIDE LN

Articles

New Menus for CLL Treatment

November 11, 2009

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with an extremely variable course. Survival after diagnosis can range from months to decades. As the pathogenesis of the disease is increasingly understood, we begin to unfold the molecular patterns that define the different prognostic subgroups and to develop strategies to predict the clinical course.